Sinopharm Group Co. Ltd.

SEHK:1099 Stock Report

Market Cap: HK$67.3b

Sinopharm Group Balance Sheet Health

Financial Health criteria checks 5/6

Sinopharm Group has a total shareholder equity of CN¥122.4B and total debt of CN¥95.6B, which brings its debt-to-equity ratio to 78.1%. Its total assets and total liabilities are CN¥429.6B and CN¥307.2B respectively. Sinopharm Group's EBIT is CN¥20.9B making its interest coverage ratio 11.4. It has cash and short-term investments of CN¥43.3B.

Key information

78.1%

Debt to equity ratio

CN¥95.61b

Debt

Interest coverage ratio11.4x
CashCN¥43.33b
EquityCN¥122.43b
Total liabilitiesCN¥307.15b
Total assetsCN¥429.58b

Recent financial health updates

Sinopharm Group (HKG:1099) Has A Pretty Healthy Balance Sheet

Dec 30
Sinopharm Group (HKG:1099) Has A Pretty Healthy Balance Sheet

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Aug 23
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Is Sinopharm Group (HKG:1099) A Risky Investment?

Apr 22
Is Sinopharm Group (HKG:1099) A Risky Investment?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Jan 15
Is Sinopharm Group (HKG:1099) A Risky Investment?

Recent updates

Sinopharm Group (HKG:1099) Has A Pretty Healthy Balance Sheet

Dec 30
Sinopharm Group (HKG:1099) Has A Pretty Healthy Balance Sheet

At HK$20.45, Is It Time To Put Sinopharm Group Co. Ltd. (HKG:1099) On Your Watch List?

Nov 26
At HK$20.45, Is It Time To Put Sinopharm Group Co. Ltd. (HKG:1099) On Your Watch List?

Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Nov 06
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Oct 04
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Aug 23
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Jul 27
The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Jun 16
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

May 13
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Apr 22
Is Sinopharm Group (HKG:1099) A Risky Investment?

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Mar 21
Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Mar 06
Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Jan 31
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Jan 15
Is Sinopharm Group (HKG:1099) A Risky Investment?

Financial Position Analysis

Short Term Liabilities: 1099's short term assets (CN¥382.4B) exceed its short term liabilities (CN¥283.2B).

Long Term Liabilities: 1099's short term assets (CN¥382.4B) exceed its long term liabilities (CN¥23.9B).

Debt to Equity History and Analysis

Debt Level: 1099's net debt to equity ratio (42.7%) is considered high.

Reducing Debt: 1099's debt to equity ratio has reduced from 97.2% to 78.1% over the past 5 years.

Debt Coverage: 1099's debt is well covered by operating cash flow (20.4%).

Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (11.4x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 09:09
End of Day Share Price 2024/12/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sinopharm Group Co. Ltd. is covered by 42 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason MannBarclays
Derrick SunBNP Paribas Securities (Asia)
Bo LiBofA Global Research